Proton vs standard radiation for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial is testing whether a newer, more precise type of radiation (proton therapy) works better than standard radiation (IMRT) for people with advanced nasopharyngeal cancer. It also includes chemotherapy and immunotherapy to see if the combination can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a specific type of nasopharyngeal cancer (WHO type II or III).
- Your cancer must be high-risk, advanced stage (T4 or N3) but not spread to other organs (M0).
- You cannot have had any prior treatment (like radiation, chemo, or immunotherapy) for this cancer.
- You must be in good general health (ECOG score 0 or 1) and have normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation therapy for nasopharyngeal cancer that hasn't spread. Proton therapy is a newer type that may cause fewer side effects; this study tests if it works as well as standard photon therapy.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial compares two types of radiation therapy—proton beam versus standard X-ray (photon)—for treating nasopharyngeal cancer. The goal is to see if proton therapy works as well as standard therapy while possibly causing fewer side effects.
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.